Orchid Pharma (ORCHPHARMA) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
14 Aug, 2026Executive summary
Unaudited standalone and consolidated financial results for Q1 FY 2026-27 were approved, reflecting the impact of a major amalgamation and recent international acquisitions.
Financial highlights
Standalone revenue from operations for Q1 FY27 was ₹30,417.13 lakhs, up from ₹26,318.58 lakhs year-over-year.
Standalone net profit for Q1 FY27 was ₹1,193.72 lakhs, compared to a loss of ₹240.54 lakhs in Q1 FY26.
Consolidated net profit for Q1 FY27 was ₹322.44 lakhs, compared to a loss of ₹66.13 lakhs in Q1 FY26.
Total comprehensive income (standalone) for Q1 FY27 was ₹1,194.36 lakhs.
Outlook and guidance
The company continues to monitor regulatory changes, especially regarding new Labour Codes, and will adjust provisions as needed.
Latest events from Orchid Pharma
- Profits and margins fell, but acquisitions and integration set up 10–15% growth for FY27.ORCHPHARMA
Q4 25/26 - Sales and margins fell, but profitability returned at PBT/PAT despite exceptional costs.ORCHPHARMAQ3 25/26
- Q2 FY26 saw sales and margins fall, but global acquisitions support future recovery.ORCHPHARMAQ2 25/26
- Q1 FY26 sales and profits dropped sharply, but margins and strategic initiatives were maintained.ORCHPHARMAQ1 25/26
- H1 FY25 sales up 22% YoY, net profit and margins improved, Orblicef launched in India.ORCHPHARMAQ2 24/25
- Q1 sales up 34%, EBITDA up 71%, profit up 169%, with strong CapEx and Cipla partnership.ORCHPHARMAQ1 24/25
- 9M FY25 revenue up 14–15%, PAT up 26%, with stable margins and ongoing project delays.ORCHPHARMAQ3 24/25
- Double-digit sales and profit growth achieved, but margin pressure and project delays persist.ORCHPHARMAQ4 24/25